Archie Bleyer, M.D., discusses the increase in cancer rates in young people, noting the surge in thyroid and kidney cancer is at least partly a result of “overdiagnosis,” due to increased screenings for cancer and other health concerns.

In a story explaining how Oregon law doesn’t legalize psychedelics as a medical therapy and instead legalizes their “supported adult use,” Aryan Sarparast, M.D., notes promising results from a clinical trial investigating psychedelics as medical therapy

Ajit Jetmalani, M.D., highlights Oregon’s efforts to address the rising rates of suicide among young people in the U.S., citing Oregon’s youth suicide prevention strategy, which involves a suicide and depression screening at every medical appointment and having all school-run programs identify high-risk youth.

-- In an article on new treatment options for patients with gastrointestinal stromal tumors, or GIST, Michael Heinrich, M.D., says: “The key to managing these neuro-cognitive side effects is early recognition of them, modifying the dose, and doing dose interruptions.”

Continued coverage of the newly formed Knight Cancer Precision Biofabrication Hub led by Luiz Bertassoni, D.D.S., Ph.D., to develop organs, bone for pioneering research into cancer, and more.

In updated coverage about the FDA approving the nation’s first over-the-counter birth control pill, Alison Edelman, M.D., says the pill, which only has progestin and not a combination of progestin and estrogen, “is way safer than many of the medications we have over the counter currently.”

OHSU patient Megan Link recently attended the World Heart Summit, where she shared her experience living with hypertrophic cardiomyopathy as well as her participation in a clinical trial evaluating an experimental drug for the heart condition. Ahmad Masri, M.D., says: “We’re very focused on … implementing the science and trying to get more options to patients.”

OHSU research reveals only one in four adolescent residential treatment centers nationwide provide a proven medication to treat opioid use disorder despite an ever-rising number of overdose deaths.

The findings are particularly ominous because if adolescents can’t access buprenorphine at residential treatment centers, they’re unlikely to access it elsewhere, said Caroline King, a physician-researcher who conducted the research while studying for her medical degree at Oregon Health and Science University.

OHSU research reveals only one in four adolescent residential treatment centers nationwide provide a proven medication to treat opioid use disorder despite an ever-rising number of overdose deaths. Todd Korthuis, M.D., says, “As somebody who’s tried to promote the use of evidence-based treatment for addiction my whole career, it’s just jaw-dropping.”